Department of Otolaryngology, The Medical Centre of Postgraduate Education, 01-813 Warsaw, Poland.
Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, 93053 Regensburg, Germany.
Int J Mol Sci. 2023 Jul 31;24(15):12277. doi: 10.3390/ijms241512277.
Cholesteatoma is a temporal bone disease characterized by dysfunctions of keratinocytes. MicroRNAs (miRNAs) are evolutionary conserved noncoding RNAs that regulate mRNA expression. They can be packaged into exosomes and transported to target cells that can be used in the future therapy of cholesteatoma. This study aimed to collect knowledge on the role of miRNAs and exosomal miRNAs in cholesteatoma and was conducted according to the PRISMA guidelines for systematic reviews. Four databases were screened: Pubmed/MEDLINE, Web of Science, Scopus, and the Cochrane Library. The last search was run on the 6th of June 2023. We included full-text original studies written in English, which examined miRNAs in cholesteatoma. The risk of bias was assessed using the Office of Health Assessment and Translation (OHAT) Risk of Bias Rating Tool, modified for the needs of this review. We identified 118 records and included 18 articles. Analyses revealed the downregulation of exosomal miR-17 as well as miR-10a-5p, miR-125b, miR-142-5p, miR34a, miR-203a, and miR-152-5p and the overexpression of exosomal miR-106b-5p as well as miR-1297, miR-26a-5p, miR-199a, miR-508-3p, miR-21-3p, miR-584-5p, and miR-16-1-3p in cholesteatoma. The role of differentially expressed miRNAs in cholesteatoma, including cell proliferation, apoptosis, the cell cycle, differentiation, bone resorption, and the remodeling process, was confirmed, making them a potential therapeutic target in this disease.
胆脂瘤是一种颞骨疾病,其特征为角蛋白细胞功能障碍。微小 RNA(miRNA)是进化上保守的非编码 RNA,可调节 mRNA 表达。它们可以被包装到外泌体中,并被运输到靶细胞,这在未来胆脂瘤的治疗中可能会被应用。本研究旨在收集 miRNA 和外泌体 miRNA 在胆脂瘤中的作用的相关知识,并根据系统评价的 PRISMA 指南进行。共筛选了 4 个数据库:Pubmed/MEDLINE、Web of Science、Scopus 和 Cochrane Library。最后一次搜索是在 2023 年 6 月 6 日进行的。我们纳入了以英文撰写并检查胆脂瘤中 miRNA 的全文原始研究。使用针对本综述需求进行修改的 Office of Health Assessment and Translation(OHAT)风险偏倚评估工具评估偏倚风险。我们共确定了 118 条记录,纳入了 18 篇文章。分析显示,外泌体 miR-17 以及 miR-10a-5p、miR-125b、miR-142-5p、miR-34a、miR-203a 和 miR-152-5p 的下调,以及外泌体 miR-106b-5p、miR-1297、miR-26a-5p、miR-199a、miR-508-3p、miR-21-3p、miR-584-5p 和 miR-16-1-3p 的过表达与胆脂瘤有关。证实了差异表达 miRNA 在胆脂瘤中的作用,包括细胞增殖、凋亡、细胞周期、分化、骨质吸收和重塑过程,使其成为该疾病潜在的治疗靶点。